What is the recommended unit increase for Toujeo (insulin glargine)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 11, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Toujeo Dose Adjustment Guidelines

Increase Toujeo by 2 units every 3 days if fasting glucose is 140-179 mg/dL, or by 4 units every 3 days if fasting glucose is ≥180 mg/dL, until reaching a target fasting plasma glucose of 80-130 mg/dL. 1, 2

Standard Titration Algorithm

The American Diabetes Association provides clear evidence-based titration protocols that apply to all basal insulin analogs, including Toujeo 1:

  • For fasting glucose 140-179 mg/dL: Increase by 2 units every 3 days 1, 2
  • For fasting glucose ≥180 mg/dL: Increase by 4 units every 3 days 1, 2
  • Target fasting glucose: 80-130 mg/dL 1, 2
  • For hypoglycemia without clear cause: Reduce dose by 10-20% immediately 1, 2

Alternative Titration Approach

Some protocols recommend increasing by 10-15% of the current dose once or twice weekly until fasting blood glucose targets are met 2. This translates to approximately 2-4 units for most patients on moderate doses 2.

Critical Threshold: When to Stop Escalating Toujeo

Stop increasing Toujeo when the dose exceeds 0.5 units/kg/day and instead add prandial insulin or a GLP-1 receptor agonist. 1, 2 Clinical signals that you've reached this threshold include 2:

  • Basal insulin dose >0.5 units/kg/day 2
  • Bedtime-to-morning glucose differential ≥50 mg/dL 2
  • Hypoglycemia episodes 2
  • High glucose variability 2

Continuing to escalate basal insulin beyond 0.5-1.0 units/kg/day without addressing postprandial hyperglycemia leads to "overbasalization"—a dangerous pattern causing suboptimal control and increased hypoglycemia risk 2.

Important Toujeo-Specific Consideration

Toujeo (insulin glargine 300 U/mL) requires approximately 10-20% higher total daily doses compared to Lantus (insulin glargine 100 U/mL) to achieve equivalent glycemic control. 3 This is due to its more concentrated formulation and slightly different pharmacokinetic profile 3. However, the titration increments (2-4 units every 3 days) remain the same 1, 2.

Monitoring Requirements

  • Daily fasting blood glucose monitoring is essential during active titration 1, 2
  • Reassess adequacy of insulin dose at every clinical visit 1
  • Look for signs of overbasalization at each assessment 2
  • If more than 2 fasting glucose values per week are <80 mg/dL, decrease the dose by 2 units 2, 4

Common Pitfalls to Avoid

  • Never delay dose adjustments: In stable patients, adjust every 3 days—waiting longer unnecessarily prolongs time to glycemic targets 2
  • Don't ignore hypoglycemia: Always check for hypoglycemic episodes before increasing the dose 4
  • Recognize when basal insulin alone is insufficient: If A1C remains above goal after 3-6 months despite reaching fasting glucose targets, add prandial insulin or a GLP-1 receptor agonist rather than continuing to escalate Toujeo 1, 2
  • Continue metformin: Unless contraindicated, metformin should be continued when intensifying insulin therapy 2, 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Initial Dosing for Lantus (Insulin Glargine) in Patients Requiring Insulin Therapy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Insulin Dose Adjustment for Hyperglycemia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Insulin Regimen Adjustment for Severely Uncontrolled Type 2 Diabetes

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.